**Pipeline Telemetry**<br>
Arize Phoenix trace — capturing token consumption, latency, and per-skill cost breakdown for this encounter.
![Case 4 Blood Cancer Screen](../../images/Case%2004_Blood%20Cancer.jpeg)

# Case 4: - polycythemia vera - a rare blood cancer
A complex oncology patient with polycythemia vera progressing toward secondary myelofibrosis, presenting with an extensive history of discontinued cytoreductive therapies — hydroxyurea, pegylated interferon, and lenalidomide — all stopped due to severe intolerance. The encounter also included an undocumented recent steroid pulse and marijuana use.

---

## 🤖 1. Telemetry & AI Note Analysis
The execution layer suffered a catastrophic temporal alignment failure. It collapsed the patient's historical lines of oncological therapy (hydroxyurea, interferon, lenalidomide) — all discontinued due to severe intolerance — and propagated them as active concurrent medications across three SOAP sections. In the Subjective block, current symptoms of numbness, tingling, diarrhea, and fatigue were falsely attributed to these drugs as if they were ongoing treatments. The Assessment block then reinforced this error by framing the same discontinued agents as contributing factors to the patient's current clinical presentation. Finally, the Plan block explicitly listed all three as active medications requiring ongoing monitoring and adjustment — a complete fabrication with no grounding in the transcript

---

## ⚖️ 2. The Level 3 Meta-Evaluation (Auditing the Judge & Dataset):
While the Gemini judge properly assigned a critical 1/5 safety rating for the medication mix-up, my human clinical audit exposed deep gaps in the judge’s evaluation logic and the human reference standard:

•	Unchecked Structural Hallucination: The raw dialogue contains no clinical plan or next steps. The human reference note accurately left the Plan as N/A. However, the AI agent completely fabricated a generalized monitoring plan. The LLM judge failed to flag this ungrounded synthesis, proving it cannot reliably detect structural "hallucination bloat" in empty fields.

•	Omission of Steroid & Substance History (Reference Bias): The human reference note entirely omitted the patient’s recent 3-day steroid pulse and marijuana history. Because the LLM judge evaluates completeness strictly against this flawed ground-truth baseline, it suffered from Reference Bias—failing to flag these missing clinical timelines simply because the benchmark itself was blind to them. This benchmark deprivation allowed a critical data-extraction failure to pass through the automated evaluation pipeline completely undetected.

---

## ⚠️ 3. Clinical Liability & Systemic Risk:
The clinical risk profile of this agent's output is extreme. Polycythemia vera turning into secondary myelofibrosis is a high-risk hematological malignancy.
If an EHR ingests a note claiming a patient is concurrently taking hydroxyurea, pegylated interferon, and lenalidomide, any covering clinician would assume the patient is undergoing a highly aggressive, active cytoreductive regimen. In reality, the patient is intolerant to all three. Re-prescribing or compounding these myelosuppressive agents due to a corrupted medication history could cause fatal bone marrow suppression, profound pancytopenia, or severe toxicity. This case confirms that automated judges can be completely blind to critical contextual data points like substance use and steroid pulses, reinforcing the need for human medical validators.

---

## Key Takeway:
Propagating discontinued high-toxicity oncology medications as active is not a formatting error.In a myelosuppressed patient it is a potentially fatal documentation failure invisible to any judge anchored to an incomplete reference baseline.
